Pfizer and BioNTech Propose Expansion of Pivotal COVID-19 Vaccine Trial

NEW YORK and MAINZ, GERMANY, Sept. 12, 2020 (GLOBE NEWSWIRE) --  NEW YORK and MAINZ, GERMANY, September 12 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) announced today that they have submitted an amended protocol to the U.S. Food and Drug Administration to expand the enrollment of their Phase 3 pivotal COVID-19 vaccine trial to up to approximately 44,000 participants which also allows for the enrollment of new populations.

See the original post here:
Pfizer and BioNTech Propose Expansion of Pivotal COVID-19 Vaccine Trial